Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
Message: Biodel's VIAject ultra rapid acting insulin

Just FYI: BIOD-123 phase 2 trials are expected to yield top line data in Q3 1013

http://finance.yahoo.com/news/biodel-announces-phase-2-clinical-103000896.html

Share
New Message
Please login to post a reply